Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes
Main finding · MALOResult — go to the resultHazard ratio 1.63 95% CI 1.12–2.37Authors' conclusion
In patients with MASLD and T2D, MBS, and specifically RYGB, as compared to semaglutide, may drive a relatively increased risk of MALO despite protection against MACE, the first diagnosis of cirrhosis, heart failure, and OAC.
Study context
- Population
- Patients with MASLD and T2D who had metabolic bariatric surgery (MBS) or semaglutide in 2018–2023 (TriNetX database)
- Exposure
- MBS vs semaglutide
- Outcome
- Composite of major adverse liver outcomes (MALO):
- Decompensation events
- Liver transplant
Methodological detailsTriNetX database
- TriNetX database
Main finding
MALO
Hazard ratio
1.63
95% CI 1.12–2.37
MBSvs Semaglutide
HR 1.63 (95% CI 1.12–2.37)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (CI) | |
|---|---|---|
| MALO, subgroups RYGB and SGRYGBvs Semaglutide | 2.01 (1.26–3.20) | |
| MALO, subgroups RYGB and SGSGvs Semaglutide | 0.97 (0.52–1.78) | |
| New cirrhosis (excluding pre-existing cirrhosis) | 0.46 (0.29–0.73) | |
| MACE | 0.51 (0.38–0.67) | |
| HF | 0.41 (0.27–0.62) | |
| Obesity-associated cancer (OAC) | 0.56 (0.34–0.92) | |
| All-cause mortality (ACM), subgroup RYGBRYGBvs Semaglutide | 1.64 (1.01–2.67) | |
| 0.20.5125Hazard ratio (log scale) |
All-cause mortality (ACM)
- No difference in ACM between MBS and semaglutide
Original publication
Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes. Diabetes Obes Metab. Published 13 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →